Zinbryta Lawsuit
Zinbryta has been recalled because of reports linking the multiple sclerosis (MS) drug to serious brain inflammation. Patients harmed by this medication may be eligible to file a Zinbryta lawsuit to obtain compensation for their pain and suffering.
Contact a Zinbryta Lawyer Today
The nationwide law firm of Bernstein Liebhard LLP is now investigating personal injury claims on behalf of Zinbryta patients who experienced any of the following side effects:
- Sudden brain inflammation
- Encephalitis
- Meningoencephalitis
- Wrongful death
To contact a qualified Zinbryta lawyer, please call our office at (888) 994-5118.
What is Zinbryta?
The U.S. Food & Drug Administration (FDA) approved Zinbryta in May 2016 to treat patients with relapsing MS. However, because of its association with serious and potentially life-threatening liver injuries, the FDA advised that Zinbryta only be prescribed for patients who had not responded to other MS drugs.
Zinbryta patients and doctors are also required to enroll in a Risk Evaluation and Mitigation Strategy (REMS) program to ensure that patients are properly monitored.
Why Was Zinbryta Recalled?
Less than two years after it came to market, Biogen, Inc. and AbbVie, Inc. announced that Zinbryta was being withdrawn from the global market.
“Due to the increasingly complicated benefit/risk profile of ZINBRYTA, we believe it is in the best interest of patients to withdraw ZINBRYTA. There are complicated types of adverse events being reported in patients taking ZINBRYTA,” Biogen’s announcement stated. “All adverse event reports, including new reports, continue to be evaluated.”
The March 2nd announcement came the same day that regulators in Europe launched an “urgent review” of Zinbryta following eight cases of serious inflammatory brain disorders, including sudden brain inflammation, encephalitis and meningoencephalitis.
The European Medicines Agency recommended that Zinbryta be recalled three days later, after its review uncovered a total of 12 cases of serious brain inflammation. Three of the cases were fatal.
What Should Patients Do?
According to the FDA, patients should not stop taking Zinbryta without talking to their doctor. They should contact their health care provider if they experience any new or unexplained symptoms.
Symptoms of Zinbryta brain injuries may include:
- Persistent Fever
- Severe Headaches
- Nausea
- Fatigue
- Yellowing of Skin or Eyes
Learn More About Filing a Zinbryta Lawsuit
Patients who suffered a serious brain injury, including sudden brain inflammation, encephalitis or meningoencephalitis, while taking Zinbryta may be entitled to compensation for:
- Medical bills
- Lost wages
- Pain and suffering
- Wrongful death
- More
To learn if you are eligible to file a Zinbryta lawsuit, please call (888) 994-5118.
- Biogen (2016) “Highlights of Prescribing Information” https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761029s000lbl.pdf
- FDA (2016) “FDA Approves Zinbryta to Treat Multiple Sclerosis” https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504000.htm
- EMA (2018) “EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta” http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/03/news_detail_002920.jsp&mid=WC0b01ac058004d5c1
- FDA (2018) “FDA working with manufacturers to withdraw Zinbryta from the market in the United States” https://www.fda.gov/drugs/drugsafety/ucm600999.htm
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.
Follow Us
